Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
A study led by IDIBELL and the Infanta Eleonor University Hospital in Madrid shows that 10% of patients with severe COVID-19 present neutralizing antibodies against the cytokine interferon type 1.
We found that there were epigenetic variations, the chemical switches that regulate DNA activity, in the individuals positive for the virus who developed a severe COVID-19.
The study has also permitted identify genetic variants that modify the expression of genes in the colon and that are associated with diseases such as colorectal cancer, but also with other organs such as the brain, showing the relationship between the intestine and the brain.
An investigation by the International Center for Numerical Methods in Engineering (CIMNE) and the University of Lleida (UdL), in which IDIBELL and the Hospital de Bellvitge has participated, has developed automated voice markers to identify early affectations of the disease.
To equilibrate the gene expression between XX females and XY males, one of female X chromosomes is inactivated. Researchers from IDIBELL Regenerative Program has discovered that this inactivation is affected in bone marrow aged stem cells.
A study by IDIBELL and Bellvitge Hospital establishes, for the first time, a temporary criterion for the risk of chronicity of symptoms for the different subtypes of ED.
The study describes two syndromes, which combine clinical manifestations and differential cerebrospinal fluid profiles, which determine a different prognosis in patients.
The biomarker candidate is a fragment of a neuronal receptor that can be detected in the cerebrospinal fluid.
